Tempus, a leader in artificial intelligence and precision medicine, today announced that Kate Sasser, PhD, is joining the company as its Chief Scientific Officer. Dr. Sasser brings over twenty year’s experience in translational research, precision medicine, data science, and drug discovery and development across the biotech and pharmaceutical industry. In her new role, she will be focused on utilizing cutting-edge science and the power of multimodal data to bring personalized medicine solutions to life science collaborators, physicians, and patients.
Dr. Sasser joins Tempus from Genmab, a rapidly growing biotech company focused on developing transformative antibody therapeutics as medicine, where she took on increasing responsibilities across translational research, precision medicine, data science, and R&D operations. Before Genmab, Dr. Sasser led translational research for oncology at Johnson and Johnson (Janssen PRD).
“Dr. Sasser’s insight and expertise in leading translational research in the life sciences is essential as we continue to create solutions to support novel therapeutic discovery and development,” said Eric Lefkofsky, Founder and CEO of Tempus. “She is a great addition to our team as we continue to grow and evolve as a company.”
“Tempus is combining novel approaches to deliver significant advancements in precision medicine, and I am thrilled to be joining the team at such an exciting time. I hope to leverage my experience alongside the talented team and our many collaborators to enable the delivery of personalized healthcare.” said Dr. Sasser.
Dr. Sasser graduated from Oregon State University with a bachelor’s degree in microbiology and chemistry. She received her PhD in integrated biomedical sciences from Ohio State University where she focused on identifying factors in the tumor microenvironment that contribute to metastasis and cancer progression.
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make near real-time, data-driven decisions to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.